Therapy for severe necrotizing vasculitis with infliximab.
Mang
Renz
R
Ruzicka
Thomas
T
Stege
Helger
H
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D001706:Biopsy; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069285:Infliximab; D007262:Infusions, Intravenous; D007871:Leg Ulcer / Q000150:complications / Q000473:pathology; D008875:Middle Aged; D009336:Necrosis; D009894:Opportunistic Infections / Q000276:immunology; D012008:Recurrence; D012074:Remission Induction; D013203:Staphylococcal Infections / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D014945:Wound Healing
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab